{"protocolSection":{"identificationModule":{"nctId":"NCT06052566","orgStudyIdInfo":{"id":"6024-014"},"secondaryIdInfos":[{"id":"MK-6024-014","type":"REGISTRY","domain":"MSD"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)","officialTitle":"An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-11-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-12-05","type":"ACTUAL"},"completionDateStruct":{"date":"2024-12-05","type":"ACTUAL"},"studyFirstSubmitDate":"2023-09-18","studyFirstSubmitQcDate":"2023-09-18","studyFirstPostDateStruct":{"date":"2023-09-25","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-10-03","resultsFirstSubmitQcDate":"2025-10-03","resultsFirstPostDateStruct":{"date":"2025-10-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-03","lastUpdatePostDateStruct":{"date":"2025-10-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide."},"conditionsModule":{"conditions":["Non-alcoholic Steatohepatitis","Hepatic Impairment"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":22,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Efinopegdutide in Participants with Moderate Hepatic Impairment","type":"EXPERIMENTAL","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection.","interventionNames":["Drug: Efinopegdutide"]},{"label":"Efinopegdutide in Participants with Severe Hepatic Impairment","type":"EXPERIMENTAL","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.","interventionNames":["Drug: Efinopegdutide"]},{"label":"Efinopegdutide in Healthy-Matched Control Group","type":"EXPERIMENTAL","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.","interventionNames":["Drug: Efinopegdutide"]}],"interventions":[{"type":"DRUG","name":"Efinopegdutide","description":"Subcutaneous injection administered at a dose of 7 mg","armGroupLabels":["Efinopegdutide in Healthy-Matched Control Group","Efinopegdutide in Participants with Moderate Hepatic Impairment","Efinopegdutide in Participants with Severe Hepatic Impairment"],"otherNames":["MK-6024","HM12525A","JNJ-64565111"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-inf.","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35"},{"measure":"Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-last.","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35"},{"measure":"Maximum Plasma Concentration (Cmax) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the Cmax.","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35"},{"measure":"Time to Maximum Concentration (Tmax) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the Tmax of efinopegdutide.","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35"},{"measure":"Apparent Terminal Half-life (t/12) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the t1/2.","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35"},{"measure":"Apparent Total Clearance (CL/F) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the CL/F.","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35"},{"measure":"Apparent Volume of Distribution (Vz/F) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the Vz/F.","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35"}],"secondaryOutcomes":[{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.","timeFrame":"Up to 35 days"},{"measure":"Number of Participants Who Discontinued Study Intervention Due to an AE","description":"An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.","timeFrame":"Up to 35 days"}]},"eligibilityModule":{"eligibilityCriteria":"The main inclusion and exclusion criteria include but are not limited to the following:\n\nInclusion Criteria:\n\n* A participant assigned female at birth is eligible to participate if not pregnant or breastfeeding, is not a participant of childbearing potential (POCBP), or is a POCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 35 days after the last dose of study intervention.\n* For participants with moderate or severe hepatic impairment: Have a diagnosis of chronic (\\>6 months), stable, hepatic impairment with features of cirrhosis due to any etiology (stability of hepatic disease should correspond to no acute episodes of illness within the previous 2 months due to deterioration in hepatic function).\n\nExclusion Criteria:\n\n* History of cancer (malignancy).\n* Had major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.\n* Participants with moderate or severe hepatic impairment who are positive for human immunodeficiency virus (HIV)-1 or HIV-2 at the prestudy (screening) visit.\n* Participants with moderate or severe hepatic impairment who received antiviral and/or immune modulating therapy for hepatitis B virus (HBV) or hepatitis C virus (HCV) within 90 days prior to study start.\n* Healthy participants who are unable to refrain from or anticipate the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study intervention, throughout the study (including washout intervals between treatment periods), until the poststudy visit.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Clinical Pharmacology of Miami ( Site 0005)","city":"Miami","state":"Florida","zip":"33014-3616","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Advanced Pharma CR, LLC ( Site 0001)","city":"Miami","state":"Florida","zip":"33147","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Genesis Clinical Research, LLC ( Site 0006)","city":"Tampa","state":"Florida","zip":"33603","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"American Research Corporation ( Site 0002)","city":"San Antonio","state":"Texas","zip":"78215","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://www.merckclinicaltrials.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf","url":"https://externaldatasharing-msd.com/"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"FG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"FG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"BG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"BG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"22"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.5","spread":"9.5"},{"groupId":"BG001","value":"48.5","spread":"10.5"},{"groupId":"BG002","value":"56.2","spread":"7.1"},{"groupId":"BG003","value":"53.9","spread":"9.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"15"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"19"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"21"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-inf.","populationDescription":"All participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hr*μg/mL","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","lowerLimit":"120","upperLimit":"169"},{"groupId":"OG001","value":"152","lowerLimit":"106","upperLimit":"219"},{"groupId":"OG002","value":"146","lowerLimit":"81.8","upperLimit":"262"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio","paramValue":"0.97","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.61","ciUpperLimit":"1.54"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio","paramValue":"1.04","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"1.71"}]},{"type":"PRIMARY","title":"Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-last.","populationDescription":"All participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"hr*μg/mL","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","lowerLimit":"113","upperLimit":"156"},{"groupId":"OG001","value":"125","lowerLimit":"80.8","upperLimit":"193"},{"groupId":"OG002","value":"134","lowerLimit":"70.2","upperLimit":"255"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio","paramValue":"0.99","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.60","ciUpperLimit":"1.65"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio","paramValue":"0.93","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.53","ciUpperLimit":"1.65"}]},{"type":"PRIMARY","title":"Maximum Plasma Concentration (Cmax) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the Cmax.","populationDescription":"All participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"μg/mL","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.348","lowerLimit":"0.282","upperLimit":"0.429"},{"groupId":"OG001","value":"0.404","lowerLimit":"0.242","upperLimit":"0.675"},{"groupId":"OG002","value":"0.474","lowerLimit":"0.253","upperLimit":"0.890"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio","paramValue":"0.73","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.44","ciUpperLimit":"1.21"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio","paramValue":"0.85","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.47","ciUpperLimit":"1.53"}]},{"type":"PRIMARY","title":"Time to Maximum Concentration (Tmax) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the Tmax of efinopegdutide.","populationDescription":"All participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hour","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.00","lowerLimit":"96.00","upperLimit":"310.93"},{"groupId":"OG001","value":"72.04","lowerLimit":"24.00","upperLimit":"144.00"},{"groupId":"OG002","value":"83.78","lowerLimit":"48.00","upperLimit":"167.25"}]}]}]},{"type":"PRIMARY","title":"Apparent Terminal Half-life (t/12) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the t1/2.","populationDescription":"All participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hour","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":"13.5"},{"groupId":"OG001","value":"149","spread":"26.0"},{"groupId":"OG002","value":"115","spread":"32.3"}]}]}]},{"type":"PRIMARY","title":"Apparent Total Clearance (CL/F) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the CL/F.","populationDescription":"All participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"L/hr","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0491","spread":"16.5"},{"groupId":"OG001","value":"0.0460","spread":"40.8"},{"groupId":"OG002","value":"0.0478","spread":"60.0"}]}]}]},{"type":"PRIMARY","title":"Apparent Volume of Distribution (Vz/F) of Efinopegdutide","description":"Blood samples collected at multiple timepoints post-dose were used to determine the Vz/F.","populationDescription":"All participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liters","timeFrame":"At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"17.9"},{"groupId":"OG001","value":"9.88","spread":"57.8"},{"groupId":"OG002","value":"7.94","spread":"91.7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.","populationDescription":"All participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to 35 days","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Study Intervention Due to an AE","description":"An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.","populationDescription":"All participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to 35 days","groups":[{"id":"OG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection."},{"id":"OG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."},{"id":"OG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Up to 35 days","description":"All-Cause Mortality is reported for all randomized participants. Serious adverse events and other adverse events are reported for all participants who received treatment.","eventGroups":[{"id":"EG000","title":"Efinopegdutide in Participants With Moderate Hepatic Impairment","description":"Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":1,"seriousNumAtRisk":8,"otherNumAffected":2,"otherNumAtRisk":8},{"id":"EG001","title":"Efinopegdutide in Participants With Severe Hepatic Impairment","description":"Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":4,"otherNumAtRisk":8},{"id":"EG002","title":"Efinopegdutide in Healthy-Matched Control Group","description":"Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":4,"otherNumAtRisk":6}],"seriousEvents":[{"term":"Multiple injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6}]}],"otherEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":6}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":6}]},{"term":"Hepatic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":6}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@msd.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2023-07-31","uploadDate":"2025-10-03T09:24","filename":"Prot_SAP_000.pdf","size":792423}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D065626","term":"Non-alcoholic Fatty Liver Disease"}],"ancestors":[{"id":"D005234","term":"Fatty Liver"},{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"}]}},"hasResults":true}